Senores Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 45.00 Cr
as on 15-05-2024
- Paid Up Capital ₹ 32.20 Cr
as on 15-05-2024
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 45.00 Cr
as on 15-05-2024
- Satisfied Charges ₹ 9.95 Cr
as on 15-05-2024
- Revenue 3.70%
(FY 2023)
- Profit 525.22%
(FY 2023)
- Ebitda -290.46%
(FY 2023)
- Net Worth 13.18%
(FY 2023)
- Total Assets 87.70%
(FY 2023)
About Senores Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 45.00 Cr and a paid-up capital of Rs 32.20 Cr.
The company currently has active open charges totaling ₹45.00 Cr. The company has closed loans amounting to ₹9.95 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Senores Pharmaceuticals Limited India is Nidhi Kapadia as COMPANY SECRETARY. Sanjay Majmudar, Manjula Shroff, Deval Shah, and Nine other members serve as directors at the Company.
- CIN/LLPIN
U24290GJ2017PLC100263
- Company No.
100263
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Senores Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nidhi Kapadia | Company Secretary | Current | |
Swapnil Shah  | Managing Director | 26-Dec-2017 | Current |
Board Members(11)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ashokbhai Barot | Director | 15-May-2018 | Current |
| Arpit Shah | Director | Current | |
| Sanjay Majmudar | Director | Current | |
| Manjula Shroff | Director | Current | |
| Deval Shah | Director | 01-Jan-2020 | Current |
| Udayan Choksi | Additional Director | 11-May-2024 | Current |
Financial Performance and Corporate Structure Insights of Senores Pharmaceuticals.
Senores Pharmaceuticals Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.7% increase. The company also saw a substantial improvement in profitability, with a 525.22% increase in profit. The company's net worth Soared by an impressive increase of 13.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Senores Pharmaceuticals?
In 2023, Senores Pharmaceuticals had a promoter holding of 63.14% and a public holding of 36.86%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Relius Lifesciences Private LimitedActive 8 years 27 daysArpit Shah and Swapnil Shah are mutual person
Ratnatris Pharmaceuticals Private LimitedActive 18 years 11 monthsArpit Shah, Swapnil Shah and 1 more are mutual person
M & B Engineering LimitedActive 43 years 6 monthsSanjay Majmudar and Udayan Choksi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Jul 2023 | ₹5.00 Cr | Open |
Hdfc Bank Limited Creation Date: 31 Dec 2022 | ₹40.00 Cr | Open |
Axis Bank Limited Creation Date: 29 Aug 2020 | ₹9.95 Cr | Satisfied |
How Many Employees Work at Senores Pharmaceuticals?
Senores Pharmaceuticals has a workforce of 48 employees as of Jul 11, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Senores Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Senores Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
